|
Name |
Octadecyl 2,2,2-trifluoroacetate
|
Molecular Formula | C20H37F3O2 | |
IUPAC Name* |
octadecyl 2,2,2-trifluoroacetate
|
|
SMILES |
CCCCCCCCCCCCCCCCCCOC(=O)C(F)(F)F
|
|
InChI |
InChI=1S/C20H37F3O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-25-19(24)20(21,22)23/h2-18H2,1H3
|
|
InChIKey |
YZVKTRPQHJKFOD-UHFFFAOYSA-N
|
|
Synonyms |
octadecyl 2,2,2-trifluoroacetate; 79392-43-1; Octadecyl trifluoroacetate; Trifluoroacetic acid, n-octadecyl ester; Acetic acid, trifluoro-, octadecyl ester; 1-Octadecanol, trifluoroacetate; SCHEMBL4361492; octadecyl2,2,2-trifluoroacetate; DTXSID80335044; Trifluoroacetic acid octadecyl ester; MFCD26792329; ZINC97972219; AS-75994; CS-0152199; FT-0698986; D82730
|
|
CAS | 79392-43-1 | |
PubChem CID | 522719 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 366.5 | ALogp: | 9.9 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 18 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 25 | QED Weighted: | 0.198 |
Caco-2 Permeability: | -5.051 | MDCK Permeability: | 0.00000983 |
Pgp-inhibitor: | 0.01 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.001 | 20% Bioavailability (F20%): | 0.999 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.033 | Plasma Protein Binding (PPB): | 98.74% |
Volume Distribution (VD): | 3.069 | Fu: | 1.10% |
CYP1A2-inhibitor: | 0.135 | CYP1A2-substrate: | 0.176 |
CYP2C19-inhibitor: | 0.388 | CYP2C19-substrate: | 0.056 |
CYP2C9-inhibitor: | 0.109 | CYP2C9-substrate: | 0.903 |
CYP2D6-inhibitor: | 0.218 | CYP2D6-substrate: | 0.05 |
CYP3A4-inhibitor: | 0.268 | CYP3A4-substrate: | 0.044 |
Clearance (CL): | 3.999 | Half-life (T1/2): | 0.019 |
hERG Blockers: | 0.413 | Human Hepatotoxicity (H-HT): | 0.023 |
Drug-inuced Liver Injury (DILI): | 0.207 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.019 | Maximum Recommended Daily Dose: | 0.012 |
Skin Sensitization: | 0.805 | Carcinogencity: | 0.151 |
Eye Corrosion: | 0.988 | Eye Irritation: | 0.97 |
Respiratory Toxicity: | 0.957 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002300 | 0.959 | D00AOJ | 0.575 | ||||
ENC001157 | 0.829 | D07ILQ | 0.548 | ||||
ENC003065 | 0.779 | D00FGR | 0.526 | ||||
ENC003066 | 0.720 | D0Z5SM | 0.512 | ||||
ENC003041 | 0.707 | D05ATI | 0.444 | ||||
ENC001243 | 0.700 | D0O1PH | 0.417 | ||||
ENC001161 | 0.696 | D00STJ | 0.405 | ||||
ENC000424 | 0.693 | D0T9TJ | 0.355 | ||||
ENC000497 | 0.684 | D00MLW | 0.339 | ||||
ENC000527 | 0.667 | D0P1RL | 0.330 |